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DISPARITIES IN INPATIENT COVID-19 CLINICAL TRIAL ELIGIBILITY 
AND ENROLLMENT ACROSS AGE, SEX, RACE, ETHNICITY 
JASMINE HIGGINS  
ABSTRACT 
COVID-19 is caused by a novel coronavirus which has a high affinity for ACE-2 
receptors in respiratory epithelium. The high affinity for ACE-2 allows the virus to 
infiltrate cells leading to viral assembly, maturation, and release. COVID-19 presents itself 
with respiratory and cold-like symptoms which may ultimately develop into ARDS. This 
study analyzed the demographics of inpatients who tested positive at MGH as well as their 
eligibility and enrollment status for COVID-19 clinical trials. When looking at the study 
population, MGH and the state of Massachusetts shared similar distributions of 
hospitalized men and women. MGH had a slightly higher proportion of Non-Hispanic 
Black hospitalized patients and a lower proportion of Hispanic hospitalized patients 
compared to the state of MA. MGH also had a higher percent of hospitalized patients 65 
and older compared to the state. This study found statistically significant differences among 
eligibility status and enrollment status across race/ethnicity and age. There were no 
statistically significant differences among eligibility status or enrollment status across sex. 
Differences among eligibility and enrollment status among those 65 and older may be due 
to the large elderly population that utilizes MGH for care. It may also coincide with the 
likelihood of longer hospital stays. The differences between eligibility and enrollment 
status across race/ethnicity may have to do with the hospital’s program dedicated to clinical 
	
	 vi 
trial inclusion of Spanish speaking patients. Findings from this study exemplify MGH’s 
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SARS-CoV-2: A Novel Coronavirus  
 
COVID-19 or corona (CO) virus (VI) disease (D) from 2019 is caused by a novel, 
human-infecting coronavirus known as the severe acute respiratory syndrome coronavirus 
two or SARS-CoV-2. It was first discovered when several patients with pneumonia were 
found linked to the Huanan wet seafood market in Wuhan, China. The novel strain was 
identified using next-generation sequencing of RNA extracted from bronchoalveolar 
lavage fluid samples from infected patients (Zhu et al., 2019). The genome sequences 
extracted from the patients exhibited more than 99.98% sequence similarity suggesting 
infection by the same virus. These sequences also exhibited high similarity to two bat 
SARS-like coronaviruses (Zhu et al., 2019; Zhou et al., 2019). Notably, SARS-CoV-2 is 
less similar to SARS-CoV and MERS-CoV, both known human-infecting coronaviruses 
(Lu et al., 2019) 
Like all other coronaviruses, SARS-CoV-2 is an enveloped, single-stranded, 
positive-sense RNA virus. It has a viral envelope coated by spike (S) glycoproteins and 
membrane proteins. SARS-CoV-2 attaches to the host cell using the S1 subunit of the S 
glycoprotein. The S1 subunit binds to the host membrane angiotensin-converting enzyme 
ACE-2. Binding of S1 triggers a conformational change in the S2 subunit bringing the viral 
membrane and the host cell’s membrane into close proximity, enabling fusion (Zumla et 
al., 2019). ACE-2, thus acts as a viral entry receptor.  Inside the host cell, the viral genome 
is replicated leading to viral assembly, maturation, and release (Zumla et al., 2019). The 
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following diagram illustrates this mechanism of cell infiltration and the structure of the 
virus.  
 
Figure 1. SARS-CoV-2 Virus Structure and Replication Cycle. Retrieved from BMJ 
Virology, transmission, and pathogenesis of SARS-CoV-2 (2020). 
While SARS-CoV-2 shares a higher genetic similarity to bat coronaviruses, 
it remains part of a family of human-infecting coronaviruses like SARS-CoV which causes 
a similar severe respiratory syndrome. Unlike its successor, SARS-CoV was contained 
before achieving pandemic status (Cevik et al., 2019). Like all coronaviruses, SARS-CoV-
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1 binds to the ACE-2 receptor, although with lower affinity than SARS-CoV-2. Structural 
differences in SARS-CoV-2 surface proteins enable stronger binding to the ACE-2 
allowing for increased affinity and enhanced entry into the cell. Insofar, the novel virus’ 
ability to infect the respiratory tract is improved making SARS-CoV-2 a much more potent 
virus (Cevik et al., 2019).  
Another notable difference between SARS-CoV and SARS-CoV-2 involves viral 
load kinetics and time and length of infectiousness. Peak viral load or the highest 
concentration of the virus in the respiratory tract is observed at the time of symptom onset, 
usually within the first week of illness. When the respiratory tract contains the highest 
concentration of the virus, each respiratory droplet expelled contains the highest 
concentration of the virus that can be spread and transmitted. This concept is also known 
as peak infectiousness. Since peak infectiousness occurs at the same time as peak viral 
load, the highest likelihood of spreading the virus is also within a week of symptom onset. 
Comparatively, SARS-CoV is shown to have high viral loads in the second week of illness 
well after symptom onset. The viral progression of SARS-CoV made for easier detection 
allowing for easier containment (Cevik et al., 2019). Understanding viral load kinetics and 
peak infectiousness is important for creating and encouraging protective health behaviors 
to minimize transmission. The diagram below illustrates the disease course and viral load 




Figure 2. Viral load dynamics and symptom onset. Retrieved from BMJ  
Virology, transmission, and pathogenesis of SARS-CoV-2 (2020) which was adapted from 
Snapshot: COVID-19 by Oberfeld et. Al, 2020, Cell, 181.  
Transmission of the Virus 
Considering SARS-CoV-2’s affinity for ACE-2 receptors in the epithelium of the 
respiratory tract, the main mechanism of transmission is through inhalation of infected 
respiratory droplets. The upper airway is the main target for this virus as the host cell 
receptors are mainly found in human respiratory epithelium and this tissue is in direct 
contact with the outside world (Hui et al., 2020). Although the respiratory tract serves as 
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the main target for the virus, the conjunctiva and gastrointestinal tracts are also susceptible 
to infection due to expression of ACE-2 receptors on these tissues as well (Hui et al., 2020). 
Direct contact with infected droplets or indirect contact by hands transferring infected 
droplets to the mucous membranes of the nose and mouth are also known routes of 
transmission (Hui et al., 2020).   
Preventative Measures  
The primary modes of transmission of SARS-CoV-2 through respiratory droplets 
and contact with mucosa allow for simple preventative measures. This includes social 
distancing and face coverings. These methods have been shown to greatly reduce the 
spread of the virus (Li et al., 2020; VoPham et al., 2020). Social distancing refers to a 
distance of 2 meters between two people. Social distancing also includes the state policies 
related to stay-at-home orders which refers to limiting activities outside of the home 
(Massachusetts Department of Public Health, 2020). Stay-at-home orders were successful 
in reducing the spread of the disease showing a high degree of association in reducing 
COVID-19 incidence and mortality (VoPham et al., 2020). It is also recommended that 
those who have tested positive or who have been in contact with someone who has tested 
positive should isolate themselves in order to contain the number of possible contacts and 
reduce the spread (Kumaravel et al., 2020).  
Alongside social distancing, the CDC recommends wearing a face mask that covers 
the nose and mouth (2020). Face masks act as a barrier blocking the flow of respiratory 
droplets. They also act as a filter preventing the inhalation of infected droplets (Kumaravel 
et al., 2020). 
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 In addition to these preventative measures, the public is advised to regularly wash 
hands, use hand sanitizer, and disinfect surfaces (CDC, 2020). Although evidence shows 
that the COVID-19 virus remains viable on smooth surfaces for many hours and even days, 
common disinfectants can inactivate it (Chin et al., 2020). Regularly washing hands and 
using disinfectants prevents people from touching infected surfaces and transferring 
infected particles to the mucous membranes of their eyes, nose, and mouth (Kumaravel et 
al., 2020). Following CDC guidelines by wearing a face mask, social distancing, and 
washing hands and surfaces regularly greatly decreases risk of transmission and infection 
(2020). Below is a poster publicized by the CDC that emphasizes these public health 
recommendations.  
 
Figure 3. COVID-19 Guidelines to Stop the Spread of Germs. Retrieved from the Center 




COVID-19 Disease Course 
COVID-19 presents as a fever, cough, fatigue, and shortness of breath which are 
the most common clinical features (Samudrala et al., 2020). Further along in the disease 
course, patients may develop pneumonia and require supplemental oxygen. In its most 
extreme form, COVID-19 pneumonia can develop into acute respiratory distress syndrome 
or ARDS which is usually fatal (Samudrala et al., 2020).  
Returning back to the mechanism, once the virus attaches to the host cell, ACE 2 is 
internalized (See Figure 2). Internalization of ACE-2 is likely followed by an increased 
production of angiotensin II from the ACE-1 receptor. An in increased production of 
angiotensin II increases permeability in lung tissue leading to injury. The virus may also 
activate macrophages resulting in a downstream immunological reaction through pro-
inflammatory cytokines and chemokines (Mangalmurti & Hunter, 2020). The increased 
production of cytokines and chemokines further damages epithelial cells by allowing 
infiltrates to enter the lung (Samudrala et al., 2020). Evidence shows that there is a known 
correlation between increased levels of cytokines and severe pneumonia. Increased levels 
of cytokines were also observed in patients with severe illness compared to those 
experiencing COVID-19 with lesser severity (Wu et al., 2020; Liu et al.,2020).  
Co-morbidities and COVID-19 Severity 
The severity of the illness relies on a multitude of factors. Older age, hypertension 
(HTN), cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), 
diabetes, and obesity are known risk factors associated with severe illness development, 
including the needs for hospitalization and death (Wu et al., 2020). There are direct, strong 
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correlations between underlying conditions and severe clinical outcomes, length of stay, 
and mortality (Cevik et al., 2020). Clinical comorbidities like HTN, CVD, COPD, and 
obesity may be exacerbated by COVID-19. Underlying hypertension may increase 
susceptibility to pulmonary hypertension while pneumonia due to COVID can further 
increase this risk leading to greater illness severity. A history of cardiovascular disease and 
a current COVID-19 infection may further increase the risk of a heart attack. The presence 
of COPD increases the likelihood of severe hypoxemia during COVID-19 illness. Obesity 
increases COVID-19 severity due to possible underlying low-grade abdominal 
inflammation. Baseline inflammation from a higher amount of abdominal fat may increase 
susceptibility to inflammation due to COVID-19 (Cevik et al., 2020). 
Structural Determinants  
Social distancing is the most recommended preventative measure during the 
pandemic (Center for Disease Control, 2020). Reducing contact with individuals has shown 
to greatly reduce the spread of COVID-19 (Li et al., 2020; VoPham et al., 2020). Therefore, 
the inability to work from home increases the risk of infection. Workers and businesses 
considered “essential” must stay open even during state mandated “stay-at-home” orders 
which require residents to remain at home unless they need to leave to complete necessary 
activities like grocery shopping or picking up prescriptions (Massachusetts Department of 
Public Health, 2020). Non-Hispanic Blacks and Hispanics are more likely to work in jobs 
considered “essential” compared to their Non-Hispanic White counterparts (Rogers et al., 
2020). Data from the US Bureau of Labor Statistics shows that only 19.7% of Non-
Hispanic Black workers and 16.2% of Hispanic workers were able to work from home 
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compared to the 29.9% of Non-Hispanic White workers (2020). Since more Non-Hispanic 
Black workers and Hispanic workers must continue to work outside of the home, they are 
at an even greater risk of transmission and infection of COVID-19. Furthermore, low-
income populations and populations with more essential workers participate in less social 
distancing, likely because they have reduced access to occupational protections and paid 
leave (Rogers et al., 2020). The clear gap in the ability to social distance adds to the 
increased rates of COVID infection and hospitalizations in communities of color. 
Notably, while many minorities are unable to social distance due to occupational 
requirements, others are limited due to their living situation. Close to 50% of Non-Hispanic 
Blacks live under conditions of hyper-segregation and concentrated poverty (Massey, 
2004). These conditions render high-density housing for these communities which limit 
social distancing adherence at home increasing vulnerability to COVID-19 infection and 
transmission among family members.  
Many minority communities also have reduced access to testing centers. Analysis 
of SARS-CoV-2 testing in a multistate network of centers showed small racial differences 
in testing and positivity rates. However, there were greater differences between ethnicity, 
preferred language, and insurance status (Romero et al., 2020). Reduced access to testing 
limits early detection rates and subsequent transmission prevention. With more individuals 
unaware of their infection status in areas with more uninsured residents and English as a 
second language residents, the higher the likelihood of viral transmission and thus 
increased rates of positivity (Abedi et al., 2020).   
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Since Non-Hispanic Blacks and Hispanics make up a large proportion of those 
living in poverty, unsurprisingly minorities also make up a high percentage of the homeless 
population. Specifically, African Americans make up 39% of the homeless population, 
Hispanics make up 23%, and American Indian, Alaska Native, and Pacific Islander/Native 
Hawaiian make up 5% (US Department of Housing and Urban Development, 2021). The 
lack of shelter limits the ability to social distance and self-isolate making the homeless 
population exceptionally vulnerable to infection and spread of COVID-19.  
While social distancing has been a huge protective factor in preventing the spread 
of COVID-19, insurance status has also been shown to decrease the risk of developing 
severe COVID-19. Hispanics and Non-Hispanic Blacks are three and two times more 
likely, respectively, to be uninsured compared to Non-Hispanic Whites (US Census 
Bureau, 2020).  Without access to health insurance, individuals were unable to afford 
necessary medications and medical costs. Additionally, these individuals may seek 
healthcare when they are at their sickest. Decreased health due to fewer medical checkups, 
medication noncompliance, and severe illness presentation may be determining factors for 
higher rates of COVID-19 mortality among these populations (Himmelstein & 
Woolhandler, 2020).  
Considering insurance is tied to employment, the increased rate of unemployment 
means that many more Americans are no longer insured. To add to this, family members 
who have relied on health insurance by the family’s sole provider are also no longer 
insured. Currently, 10.1 million workers are unemployed and 28.9 million Americans are 
uninsured (US Census Bureau, 2020). Since health insurance is a protective factor, the 
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increasing rates of unemployment further adds to the lack of healthcare access in many 
communities (Abedi et al., 2020).  
Individual and Socioeconomic Determinants   
Considering the many layers of structural barriers in minority communities, it is not 
surprising that the prevalence of Non-Hispanic Black deaths from COVID-19 (20.76%) 
was much higher than the US unweighted population of Non-Hispanic Blacks (12-14%) 
(Rogers et al., 2020). As previously mentioned, more Non-Hispanic Blacks and Hispanic 
workers are considered “essential”. Additionally, these workers are more likely to live in 
high-density housing and be uninsured (Massey, 2004; US Census Bureau, 2020). 
Alongside these structural determinants, African Americans and Non-Hispanic Blacks 
have the highest prevalence of hypertension in the US (Thorpe et al., 2016). Hypertension 
is the most significant comorbidity related to severe COVID-19 disease development 
(Cevik et al., 2020). The increased prevalence of hypertension in the US may be related to 
the concept of the “weathering hypothesis”. This hypothesis asserts that the health of 
African Americans deteriorates prematurely compared to White Americans as a 
consequence of long-term exposure to social and environmental risk factors. When looking 
at hypertension, African Americans exhibited equivalent prevalence rates 10 years earlier 
than Whites (Thorpe et al., 2016).  
The “weathering hypothesis” recognizes environmental factors such as living in 
poverty. Specifically, in Massachusetts, 25.2% of Latinos make up those living in poverty, 
African Americans make up 17.9%, Asian Americans make up 15.7%, Native Americans 
make up 20.3%, and Whites make up 8.3% (US Census Bureau, 2019). Those who live in 
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low-income neighborhoods typically have limited access to healthy food and quality 
healthcare. Of note, grocery mobility was strongly associated with COVID-19 mortality 
(Abedi et al., 2020).  Those who had limited access to healthy produce were more likely to 
experience worse outcomes in regards to COVID-19. The environmental factors related to 
healthcare, food, and the stress of living in poverty underline the idea behind weathering 
hypothesis. It may be one explanation as to why African Americans and Hispanics tend to 
experience poorer health in general compared to White Americans. (Abedi et al., 2020). 
COVID-19 Burden in Massachusetts  
In order to understand how COVID-19 impacted MGH, it is important to 
understand how COVID-19 impacted the state of Massachusetts. The Massachusetts 
Department of Public Health reported in August 2020 that 45% of cases in MA were men 
and 55% were women. When looking at the racial/ethnic trends of COVID-19, 31% of 
cases were Non-Hispanic White, 19.6% were Hispanic, 9.3% were Non-Hispanic Black, 
5.5% were Non-Hispanic Other, and 2.1% were Non-Hispanic Asian. When looking at the 
race/ethnicity of those hospitalized in MA due to COVID-19, 49.7% were White, 13.7% 
were Hispanic, 11.8% were Non-Hispanic Black, 7.8% were Non-Hispanic Other, and 





Figure 4. Total COVID-19 Cases and Hospitalizations by Race and Ethnicity. Retrieved 
from Massachusetts Department of Public Health COVID-19 Dashboard 2020. 
 
Figure 5. Total COVID-19 Cases by Sex. Retrieved from Massachusetts Department of 




Figure 6. Total Massachusetts COVID-19 Hospitalizations by Age Group. Retrieved 
from Massachusetts Department of Public Health COVID-19 Dashboard 2020. 
 Of those hospitalized for COVID-19 in Massachusetts during the first phase of the 
pandemic, 62.0% were 65 and older. Even more notable, those who were 80 and older 
made up 30.8% of hospitalizations.  
Population Characteristics of MGH Patients  
When looking at the demographics of Massachusetts General Hospital, 14% of 
inpatients and 23% of outpatients are Latino or African American (MGH Diversity and 
Cultural Competence, 2020). 
Specific Aims  
The goal of this research is to outline the demographics among COVID-19 
hospitalized patients who were eligible and those who ultimately enrolled at Massachusetts 
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General Hospital during the earliest phase of the COVID-19 pandemic in 2020. This 
research specifically hopes to investigate differences between age, sex, and race/ethnicity. 
We want to identify any possible differences in eligibility and enrollment between those 
who were below 65 and those who were 65 and older. We also hope to investigate any 
differences in eligibility and enrollment between men and women. Lastly, we aim to 
identify possible differences in enrollment status among White, Black, Hispanic, Asian, 
and other race/ethnicities.  
The results from this investigation will help clinical teams identify any differences 
across age, sex, and race/ethnicity between those eligible and those who enrolled in 
COVID-19 clinical trials. This investigation will also provide a sketch of the larger picture 
of those infected by COVID-19 in Boston and surrounding areas. Additionally, it will 
document the demographics of the communities that utilize MGH for their medical care. 
This paper will also serve as a point of comparison between MGH and the state of 
Massachusetts. COVID-19 research provided by the health department of the state of 
Massachusetts from April, 2020 to August, 2020 was used to compare the state’s 
distribution of demographics among COVID-19 hospitalization across age group, sex, and 
race/ethnicity to MGH’s. Ultimately, this paper will use the information it finds to 









The COVID-19 inpatient trials data was collected from EPIC, a health information 
technology program that contains patient medical records. Patients who enter the hospital 
and test positive for SARS-COV-2 or “COVID-19” are flagged by EPIC. Additionally, 
patients who are admitted and test positive on admission are also recorded. It should be 
noted that patients who were discharged from the ED or visited MGH as an outpatient were 
not considered for inpatient COVID-19 clinical trials as these trials were only administered 
in an inpatient setting. EPIC provides a report that includes the patients that are flagged by 
EPIC and those that are admitted with COVID-19. In order to capture all patients in a 24hr 
interval, data from the day of screening and two days prior are collected. This report is then 
cross-referenced with the list of patients that were screened in the two days before the 
present screening. This was completed every day from April 9th, 2020 to July 23rd, 2020.  
Data Sets 
There were two data sets. One data set provided the eligibility and enrollment status 
of each patients. The other data set provided, age, sex, race/ethnicity, language preference, 
date of screening, and disposition at discharge. Both records connected eligibility, 
enrollment, and demographic data to a randomized patient identification number.  
Cleaning and Combining the Data  
Before data analysis commenced, the data sets were combined and cleaned. The 
two data sets were combined using the patient ID. Using the ID, we created a larger dataset 
that included age, sex, race, language, month of hospitalization, disposition at discharge, 
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eligibility status, and enrollment status of patients. In order to combine these datasets, each 
set was organized by patient ID in numerical order. Duplicate IDs from each set were 
removed even if the patients were re-hospitalized with COVID-19. Re-hospitalized 
patients could not enroll in a second trial and were more likely outside the eligibility 
window of the COVID-19 studies. Patients with missing IDs were also removed from the 
list as it could not be determined if it was a unique data point or a duplicate.   
 Defining the Variables  
AGE 
Age was calculated by using the recorded date of birth of each patient while using 
April 9th, 2020 as the starting date. Age was determined by using the excel command for 
“dated if”. Age was categorized into two categories: 65 and older and younger than 65. 
Those who were 65 and older were coded as “1” and those who were younger than 65 were 
coded as “0”.  
SEX 
Sex was recorded through EPIC and downloaded into an excel spreadsheet. Sex is 
initially taken at registration and inputted into EPIC by providers who ask patients about 
their biological sex. Gender is considered, but there were no recordings in this 
dataset.  Females were coded as “1” and males were coded as “0”.  
RACE/ETHNICITY 
Race and ethnicity in EPIC is self-identified. Patients have the option to decline as 
well as choose “Other” from the listing. The options in EPIC include White, Black or 
African American, Hispanic, Hispanic - Black, Asian, Native Hawaiian or Pacific Islander, 
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Native American or Alaskan American, and Other. White patients were coded as “0”, 
Black or African American patients were coded as “1”, Hispanic patients were coded as 
“2”, Asian patients were coded as “3”, and patients who chose “Other” were coded as 
“4”.  Those who chose Hispanic - Black were coded “2” because there were only 2 patients 
who chose this option. These patients were coded as Hispanic rather than Black because 
the Hispanic group was larger. Those who identified as Native Hawaiian/Pacific Islander 
or Native American/Alaskan American were coded as “Other”. There were only 3 patients 
who identified under those categories and creating separate categories would not be 
statistically powerful enough to run an analysis.  
ELIGIBILITY STATUS 
Eligibility was determined by trial inclusion and exclusion criteria. Since there were 
multiple trials ongoing throughout the course of COVID-19, patients were considered 
eligible if they qualified for at least one trial. Eligible patients were coded as “1” while 
ineligible patients were coded as “0”. 
ENROLLMENT STATUS 
Patients were considered enrolled if they consented to participate in any COVID-
19 inpatient trial.  Patients who enrolled were coded as “1” and patients who did not enroll 
were coded as “0”. 
Data Analysis Steps 
To determine differences in eligibility and enrollment status across age, sex, and 
race, tests of dependence were performed. 
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The number of patients eligible and enrolled were determined across sex and race. The 
average age and its standard deviation across eligible and enrolled patients were also 
determined.  
Comparing Age Across Eligibility and Enrollment 
Age was recorded as a categorical variable of either 65 and older or younger than 
65. A chi-squared test from Excel was used to determine differences between age groups 
and those who were eligible and those who were not eligible. A chi-squared test was also 
performed to determine differences between age groups and those who enrolled and those 
who did not enroll. The following hypotheses were utilized in both tests. 
Hnull: There were no differences between those 65 and older and those younger 
than 65 who were eligible (enrolled) and those who were ineligible (not enrolled). 
Halternative: There were differences between those 65 and older and those younger 
than 65 who were eligible (enrolled) and those who were ineligible (not enrolled). 
Comparing Sex Across Eligibility and Enrollment  
Sex was recorded as a categorical variable with values of “male” or “female”. In 
order to determine differences between those who were eligible and those who were not 
eligible between these two categories, a chi-squared test was performed using Excel. This 
test was also used to compare the sex of those enrolled and those who did not enroll. The 
following hypotheses were utilized in both tests. Non-binary genders were considered but 
they represented too small of a category. 
Hnull: Eligibility (enrollment)status is independent of sex. 
Halternative: Eligibility (enrollment) status is dependent on sex. 
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Comparing Race/Ethnicity Across Eligibility and Enrollment  
Race was recorded as a categorical variable with values of “White”, “Black”, 
“Hispanic”, “Asian”, “Native American/Alaska Native”, and “Other”. In order to 
determine differences between those who were eligible and those who were not eligible 
between these categories, a chi-squared test was performed using Excel. This test was also 
used to compare the race/ethnicity of those enrolled and those who were not enrolled. The 
following hypotheses were utilized in both tests. 
Hnull: There are no differences in eligibility (enrollment status) across 
race/ethnicity.  
Halternative: There are differences in eligibility (enrollment status) across 
race/ethnicity.  
Performing Chi-Squared Tests across Variables 
The patient IDs, age code, eligibility status, and enrollment status were sorted by 
category. This made it easier to compare the eligibility and enrollment status between age 
groups. A 2 x 2 table was created for both eligibility status and enrollment status. The 
expected values were determined by multiplying the total number of patients from the age 
group times the total number of patients eligible divided by the total number of patients. 
This was completed for both age groups and categories of eligible, not eligible, enrolled, 
and not enrolled. Expected values determined across sex and race/ethnicity categories as 
well. Once expected values were determined, a chi-squared test was performed using the 





Study Population  
 
There was a total of 1355 COVID-19 positive inpatients screened at Massachusetts 
General Hospital from April 9, 2020 to July 23, 2020. Thirty of these patients did not have 
an MRN or did not have data attached to their MRN. The average age of this sample was 
46.2 (SD 19.0). Additionally, the majority of the sample was over the age of 65 (82.5%). 
In the early phase of the pandemic, 43.8% of hospitalizations at MGH were female and 
56.2% were male. Of those screened who recorded their race or ethnicity, 43.9% were 















Table 1. Patient Demographics of COVID-19 Hospitalizations at MGH from April 9th 
2020 to July 23rd, 2020.  
































Male  463 248  167 544  727 (56.2%) 







































Chi-squared tests were performed within the categories of age, sex, and 
race/ethnicity against status of eligibility and status of enrollment (See Table 1). Eligibility 
status was determined to be significantly associated with age (p < 3.3 x 10-6). Enrollment 
status was also determined to be significantly associated with age (p < 1.13 x 10-13).  Sex 
was not determined to be significantly associated with eligibility nor enrollment 
status. Race and ethnicity were determined to be significantly associated with eligibility (p 
< .02 x 10-4) and enrollment (p < 2.30 x 10-9). 
Comparing MGH’s Data to the State of Massachusetts’ Data  
There was a total of 1325 COVID-19 positive patients screened and recorded at 
Massachusetts General Hospital from April 9, 2020 to July 23, 2020. Of those screened 
who recorded their race or ethnicity, 43.9% were White, 12.6% were Black, 9.9% were 
Hispanic, 3.7% were Asian, and 29.9% identified as Other. These statistics parallel the total 
number of hospitalized cases recorded by the Massachusetts Public Health Department up 
until August 3, 2020. Compared to the state’s numbers, Massachusetts General Hospital 
had a lower percentage of White patients hospitalized, a higher percentage of Black 









Table 2. Patient Demographics across Eligible population and Enrolled population  
 Eligible 
 N =801 
Enrolled  
N = 281 
AGE  






























Not Recorded 7.1% 7.5% 
The majority of hospitalizations were older, white men. Of those who were eligible, 
86.3% were 65 and older, and of those who enrolled, 94.7% were 65 and older.  
Additionally, of those eligible 57.8% were men, whereas of those enrolled, 59.4% were 
men. Across race and ethnicity, 42.6% of those eligible were white compared to the 35.2% 
of those enrolled. Among eligible patients, 12.9% were Black compared to the 8.5% of 
enrolled patients. Hispanics made up 8.0% of those eligible, but 12.5% of those enrolled. 
Asians made up 3.5% of those eligible and 3.2% of those enrolled. Those who denoted 




Figure 7. Eligible vs. Enrolled by race and ethnicity.  
In total, 35.1% of eligible patients enrolled from April 9th, 2020 to July 23rd, 2020.  
 
Figure 8. Percentage of eligible patients who enrolled as a function of race and ethnicity   
When looking at race and ethnicity, the percent of eligible patients who enrolled 

















































enrolled, 54.7% of eligible Hispanic patients enrolled, 32.1% of eligible Asian patients, 
44.9% of patients who recorded themselves as “Other” enrolled, and 36.8% of those who 
did not record their race/ethnicity enrolled. Although there is slight variation between 
race/ethnic groups, it is not clinically significant.  
 
Figure 9. Eligible vs. enrolled by sex.  
There were 155 more men hospitalized than women in this sample.  Since there was 
a larger pool of men, there were 125 more men who were eligible as well as 53 more men 
who enrolled in clinical trials. Although there were more men who were eligible and who 































Figure 10. Percentage of patients enrolled among those eligible by sex.  
Among all the patients, 33.7% of eligible women enrolled and 36.9% of eligible 
men enrolled.  Enrollment as a percentage of those eligible across sex was not considered 
clinically different. 
 















































Figure 12. Percentage of patients enrolled among those eligible by age category.  
Of those eligible, 38.5% of patients below 65 enrolled and only 13.6% of patients 
65 and older enrolled. The large difference in the percent of those eligible who enrolled 
was considered clinically significant. Those who were eligible and under 65 had enrollment 
































This study determined that eligibility was significantly associated with age and 
race. Enrollment was also significantly associated with age and race. Sex was not 
significantly associated with eligibility nor enrollment. In addition to looking at differences 
between eligibility and enrollment status, this study also investigated the percent of patients 
eligible who ultimately enrolled across age, sex, and race/ethnicity. Through these 
analyses, age was determined to be clinically different across the percent of eligible 
patients who enrolled. However, race/ethnicity and sex were determined not to be clinically 
different when looking at the percent enrolled of those eligible.  
When looking at the demographics of Massachusetts General Hospital compared 
to the state of Massachusetts’ public health records, MGH had fewer White patients and 
fewer Hispanic patients hospitalized compared to Whites and Hispanics hospitalized in the 
state of Massachusetts, respectively. Additionally, MGH’s inpatient numbers prior to 
COVID-19 show that 14% of patients are Black or Latino, whereas during the pandemic 
22.5% of inpatients were Black or Latino. There was a clear increase in hospital utilization 
from these communities.    
Public health data shows that 55% of confirmed cases were male and 45% were 
female. Similarly, MGH’s inpatient distribution across sex shows that 44.2% of patients 
were women and 55.7% were men. Notably, MGH’s burden of disease in those over 65 
hospitalized with COVID-19 was much greater than the number reported by the state. Of 
those hospitalized with COVID-19, 82% were over the age of 65, whereas the state 




A higher percentage of the inpatient population was over the age of 65 compared 
to the state of Massachusetts’ numbers. This introduces the idea that Massachusetts General 
Hospital cares for a large proportion of the state’s elderly population. The increased 
proportion of patients 65 and older explains the high proportion of patients who were 65 
and older (86.3%) among total eligible patients. Of all those who enrolled, those who were 
65 and older made up 94.6% of all enrollees. There was a significant difference between 
age groups of those who were eligible and those who enrolled (p < 3.3E-06* & p <1.13E-
09*, respectively). Additionally, 38% of those eligible in the 65 and older group enrolled 
compared to the 13.8% in the under 65 group. Those under 65 had a 3 times higher 
enrollment rate than those who were 65 and older. The noticeable difference between the 
percent enrolled of those eligible may be explained by the initial presentation of each age 
group. There is an increased likelihood that those who were older were less likely to make 
clinical trial decisions due to the severity of their COVID-19. Those who could not make 
consenting decisions themselves may have had more enthusiastic surrogates. It is also 
likely that those under 65 may have had shorter hospital stays reducing the opportunity and 
chance of enrollment. 
Sex 
Massachusetts General Hospital shared a similar distribution of men and women 
compared to data from the state of Massachusetts in regards to COVID-19 hospitalizations. 
Both the state and MGH had confirmed cases of women at around 44% and cases of men 
at 56%. The similar distribution suggests that MGH serves the same number of men and 
	
31 
women. There is no difference in hospital attendance among sex based on location of 
hospital.  When looking at the percent of eligible patients who enrolled, there was no 
statistical difference between men and women. It should be noted that 33.7% of eligible 
women enrolled and 36.9% of eligible men enrolled. These percentages are very similar 
and have no clinically significant manifestations.  
Race/Ethnicity 
Prior to the pandemic, 14% of inpatients were either Black or Latino at MGH. 
During the earliest phase, 12.6% of those hospitalized were African American and 9.9% of 
those hospitalized were Hispanic meaning a total of 22.5% were either Black or Hispanic. 
The increase in the percentage of COVID inpatients from these populations clearly show a 
discrepancy in the burden of disease among these communities. Notably, there was a 
decrease in the percent of hospitalized Hispanics at MGH compared to the state of MA. 
Many of the patients who designated “Other” or did not record their race/ethnicity were 
Spanish speaking leading us to believe that many of these patients would have self-
identified as Hispanic were they queried under different circumstances. The high rate of 
“Other” and “Not recorded” race/ethnicity designations may be due to incomplete 
registration of patients who were new to the MGH hospital system as well as arriving in 
extremis. Insofar, patients who presented with a more severe COVID illness were unable 
to make race/ethnicity designations.  
While there were differences between the percent enrolled of those eligible between 
race/ethnicity, there were no clinical differences. By this, there were no meaningful 
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differences or patterns between races/ethnicities that suggests enrollment rate in any given 
category was disproportionately too high or too low.  
Of note, however, Black patients had the lowest percent enrollment at 23.3% and 
Hispanic patients had the highest percent enrollment at 54.7%. While Black patients had 
the lowest enrollment status, White patients were the second lowest at 28.9%. The high 
enrollment rate of Hispanics may be attributed to a specific MGH program dedicated to 
clinical trial inclusion of Spanish speaking patients. This program recruited physicians who 
were committed to explaining clinical trial options to Hispanic patients at MGH. This 
program exemplified cultural competency because it recruited Hispanic physicians and 
Spanish speaking physicians.  It should be noted, that while there were still language 
barriers in these clinical trials, this program was able to overcome usual impairments 
caused by language barriers in regards to clinical trial understanding and willingness to 
participate (Salman et al., 2016).   
While the percent of eligible Black patients who enrolled was not 
disproportionately low, it was still the lowest at 23.9%. Since we did not document the 
reasons behind a patient’s deferral of enrollment, it is difficult to give a comprehensive 
explanation. It is possible that many eligible Black patients were later deemed too sick by 
the principal investigator or they may have decided against participation in clinical trials.  
If declining health was a reason behind deferral of enrollment, this explanation ties 
back to the “weathering hypothesis” (Thorpe et al., 2016).  The “weathering hypothesis” 
states that African Americans’ health declines faster as a result of extended amounts of 
exposure to social and environmental risk factors. In Massachusetts, 17.6% of Black 
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residents live at or below the poverty line compared to 8.3% of White residents. 
Considering these statistics, a higher proportion of Black patients at MGH may live at or 
below the poverty. Likely, Black patients who are the sickest are experiencing the greatest 
effects of extended exposure to environmental factors related to poverty. These include 
limited resources for acquiring healthcare, healthy food, and financial security. As 
mentioned above, many Black and Latino residents continue to work as “essential” workers 
during the pandemic (Rogers et al., 2020). The increased time, energy, and stress related 
to these roles also plays a factor in the health and well-being of these populations. Working 
stressful, long hours weathers the body even further and thus also contributes to the 
“weathering hypothesis” (Thorpe et al., 2016).  
The other reasons many Black patients may have refused enrollment in clinical 
trials may have to do with an individual’s clinical trial literacy, mistrust in the medical 
field, and the medical field’s lack of cultural competency (Wendler et al., 2005; Winter et 
al., 2018).  
Strengths 
This study had a large sample size at N = 1325. Considering these numbers were 
taken in the first 4 months of the pandemic, it has given us an adequate picture of the first 
phase of the pandemic. Additionally, we were able to capture the demographics of most of 
these patients. Many patients were new to the system, so we had to gather this information 
at initial presentation. While it is not comprehensive, it gives us the ability to compare 
MGH’s demographics to the state of MA’s demographics. This study also tells us which 
populations utilized the hospital and healthcare during the pandemic. We were able to do 
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this by comparing the demographics of the hospital in past years to the first year of the 
pandemic. 
Limitations 
While this study had a large sample size, there were limitations in recording patient 
characteristics. Sex and race/ethnicity were determined through self-identification creating 
room for bias but less bias than providers assigning sex and race/ethnicity. Patients who 
could not choose an option of which they self-identified may have chosen an option that 
was not accurate for them or decided to opt out of choosing an option entirely. The options 
for race and ethnicity were limited to White, Black, Hispanic, Hispanic-Black, Asian, 
Native American/Alaskan Native, Hawaiian Native/Pacific Islander, and Other. 
Considering 29.9% of patients identified as “Other”, there is a clear limit in choices. 
Additionally, this study was not able to determine the reasons behind a patient’s deferral. 
We did not conduct any investigations as to why a principal investigator may have deferred 
a patient or why a patient may have refused enrollment. Knowing the reasons behind 
enrollment deferrals would help us gain a better understanding of the differences behind 
enrollment status between race/ethnicities and age groups. Furthermore, understanding the 
reasons behind eligibility status would also help us determine the reasons behind eligibility 
status between race/ethnicities and age groups.  
This study was able to measure the distribution of care at MGH during the earliest 
phase of the pandemic from April 9, 2020 to July 23, 2020. Across this time frame, MGH 
treated 1355 in-patients who tested positive for COVID-19. There was an increase in the 
number of Black and Latino patients who were hospitalized at MGH during the pandemic 
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compared to previous years. In previous years, 14% of patients hospitalized were Black or 
Latino, while in 2020, 22.5% of hospitalized patients were Black or Latino. Other notable 
findings included the variation across race and age of those who were eligible and not 
eligible and those who enrolled and did not enroll. Variations across age group and 
race/ethnicities in these categories were statistically significant. This suggests there are 
differences between eligibility status and enrollment status across age and race. These 
differences may be primarily attributed to the degree of health at time of presentation to 
the hospital. Those who are older are more likely experiencing more severe presentations 
of COVID-19. Additionally, from our understanding of the weathering hypothesis, access 
to healthcare, and the role as “essential” workers, minorities like Hispanics and Black 
patients may also present sicker. In many cases, sicker patients were less likely to be 
eligible to participate as well as less likely to enroll in clinical trials when approached.   
MGH also had fewer Hispanic patients compared to the state of Massachusetts. 
According to this data, only 9.9% of patients hospitalized were Hispanic whereas the state 
recorded 13.8%. Differences in demographics may be attributed to the fact that many 
patients were new to the system and too sick to record their demographics at the time of 
presentation. While there were fewer hospitalized Hispanics, Hispanics had the highest 
enrollment rate as a percentage of those eligible. This may have to do with the fact that 
there were concerted efforts to increase Latinx clinical trial participation rates at MGH. 
These efforts were conducted by highly motivated Spanish speaking physicians.  
When screening and enrolling in the future, it would be beneficial to understand the 
reasons why a patient was not enrolled. There are many factors to consider. For example, 
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the patient may have decided they did not agree with the trial, did not understand the trial, 
or did not trust the clinical trial. On the other hand, the principal investigator may have 
deferred the patient due to complex health concerns or determined the patient was unable 
to carry out the whole of the clinical trial.    
Overall, we were able to determine the demographics of those eligible and those 
who enrolled in COVID-19 clinical trials at MGH and found that MGH was relatively 
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